Detalhe da pesquisa
1.
High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients.
Virol J;
20(1): 14, 2023 01 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36698135
2.
Antigen-Heterologous Vaccination Regimen Triggers Alternate Antibody Targeting in SARS-CoV-2-DNA-Vaccinated Mice.
Vaccines (Basel);
12(3)2024 Feb 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38543852
3.
A Candidate DNA Vaccine Encoding the Native SARS-CoV-2 Spike Protein Induces Anti-Subdomain 1 Antibodies.
Vaccines (Basel);
11(9)2023 Sep 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37766128
4.
Optimization and evaluation of a live virus SARS-CoV-2 neutralization assay.
PLoS One;
17(7): e0272298, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35901110
5.
In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms.
Front Microbiol;
12: 698944, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34248922
6.
Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2.
NPJ Vaccines;
6(1): 156, 2021 Dec 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34930909
7.
Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine.
JAMA Netw Open;
5(5): e2212073, 2022 05 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35560054